Agenda for Day 3 - Wednesday 11 November, 2026
Location: Clinical Strategy Stage
Explore critical lessons learned from failed and successful clinical trials
Gain insights into improving trial design and operational processes
Examine real world case studies to enhance future trial outcomes
- Astrid Paneda - Managing Director, Allinky Biopharma
- Rahul Agrawal - CMO and Head of R&D, Cereno Scientific
- Benjamin Vandendriessche - CEO, Digital Medicine Society (DiMe)
Location: Clinical Strategy Stage
- Explore how cellular therapy platforms are expanding from oncology into autoimmune diseases, leveraging translational and clinical insights across therapeutic areas
- Review the evolving clinical and study landscape, including emerging efficacy and safety data across oncology and autoimmune indications, and discuss lessons learned for future development strategies
- Examine how benefit–risk expectations, endpoints, regulatory considerations, and development paradigms fundamentally change when moving from oncology into chronic autoimmune diseases
- Address organizational challenges of working across multiple departments with different priorities and stakeholder expectations, including governance, resource allocation, manufacturing considerations, and portfolio prioritization
- Tobias Kampfenkel - VP, Early Clinical Development and Translational Research, Miltenyi Biomedicine
Location: Clinical Strategy Stage
Australia has become a strategic launchpad for clinical innovation, with high-quality clinical data helping companies accelerate development, support regulatory submissions, attract investment, and expand into global markets. This panel will explore how Australian-generated clinical data is being used to advance products into multinational trials and international commercialisation. The discussion will showcase examples of how clinical success in Australia can serve as the starting point for global growth, reinforcing Australia's role as a gateway to international markets.
- Jovana Milosevic - CCO, Alithia Life Sciences Pty Ltd
- Stefan Cross - CEO, Crux Biolabs
- Sophie Papaconstantinou - Business Development Manager, CMAX Clinical Research
- Kurt Lackovic - CEO, Cancer Trials Australia
- Leanne Weekes - Director of Research & Policy, Bellberry Limited
Location: Clinical Strategy Stage
Explore bold and innovative strategies, focusing on risk-taking and challenging existing literature to achieve groundbreaking results.
Learn how to design clinical trials that differentiate first-in-class therapeutics and position novel therapies for success.
Discover adaptive, platform, and basket trial designs to enhance efficiency and accelerate the development of breakthrough therapies.
- Astrid Paneda - Managing Director, Allinky Biopharma
- Thomas Jaecklin - Chief Medical Officer, Gibela Therapeutics
- Ermir Kalaj - CEO, Cellula Therapeutics SA
Location: Clinical Strategy Stage
As innovation in neglected diseases like glioblastoma (GBM) and neuroblastoma struggles to attract traditional venture capital, alternative investment models are emerging that prioritize patient impact alongside financial returns. This panel examines how mission-driven investment approaches differ from—and complement—conventional venture models in supporting breakthrough therapies for underserved patient populations.
Navigate the complex financial barriers impeding clinical development in neglected disease areas and understand their cascading effects on research timelines, patient recruitment, and overall trial success
Discover how disease-focused investment strategies and foundation-led capital models create sustainable frameworks that balance financial viability with patient impact and extended development timelines
Examine Switzerland's evolving capital ecosystem and explore how for-profit and philanthropic investment models can work in tandem to advance innovation in underserved therapeutic areas while maintaining quality standards and accelerating clinical progress
- Ermir Kalaj - CEO, Cellula Therapeutics SA
- Jean-Marc Le-Doussal - Founder & CEO, Remora Biotech
- Marion Pilorge - Head of Sourcing and Startups, Ampleia
- Poul Sorensen - Partner & EIR, Argobio Studio
Location: Clinical Strategy Stage
Learn what sponsors should evaluate when choosing a CRO and what CROs need sponsors to know about managing timeline pressures and operational constraints
Discover practical strategies for establishing transparent communication, setting realistic expectations, ensuring timely payments, and creating collaborative relationships across sponsors, CROs, and sites that ultimately serve patient needs while supporting the infrastructure required to deliver quality care
- Kayleigh Rogers - Head of Business Development, Siteworks GmbH
